Trial Profile

A Randomised Phase II Study of Enzalutamide (MDV3100) in Combination With AZD5363 in Patients With Metastatic Castration-Resistant Prostate Cancer (RE-AKT)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 22 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Capivasertib (Primary) ; Enzalutamide (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Adverse reactions; Therapeutic Use
Acronyms RE-AKT

Most Recent Events

12 Feb 2020 Results (n=13) assessing safety of enzalutamide in combination with capivasertib in patients with metastatic castration-resistant prostate cancer, published in the Annals of Oncology.
05 Aug 2019 Status changed from recruiting to completed.
07 Aug 2018 Planned End Date changed from 1 Jun 2018 to 1 Mar 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com